New studies in patients with moderate-to-severe psoriasis show greater skin clearance with Bimekizumab, a monoclonal IgG1 antibody that selectively inhibits both interleukin-17A and interleukin-17F

Study 1: Bimekizumab versus Secukinumab in Plaque Psoriasis – New England Journal of Medicine

Study 2: Bimekizumab versus Adalimumab in Plaque Psoriasis – New England Journal of Medicine

Related studies: Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase trial – The Lancet AND Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial – The Lancet